Pre-clinical laboratory data suggests that VELCADE® (bortezomib) for Injection, a proteosome inhibitor, in combination with tipifarnib, a first-in-clinic farnesyl transferase inhibitor, have synergistic activity against multiple myeloma cells.

The MMRC is facilitating a multi-center Phase I clinical trial to determine the optimal dose level of VELCADE® for Injection in combination with tipifarnib for the treatment of patients with relapsed or refractory multiple myeloma.

MMRC Member Institutions that will enroll patients are:

• City of Hope National Medical Cente
• Emory University
• University of Toronto in Toronto

Emory University and Dana-Farber Cancer Institute will conduct associated correlative science studies.

For more information about this clinical trial, contact Sandra Wear, RN, at wears@themmrc.org.